Unuvar, SongulMelekoglu, RaufTurkmen, Nese B.Yilmaz, ErcanYasar, SeymaYuce, Hande2024-08-042024-08-0420210020-72921879-3479https://doi.org/10.1002/ijgo.13666https://hdl.handle.net/11616/99844Objective: To compare the predictive value of serum levels of neopterin, periostin, YKL-40, tenascin-C (TNC), and indoleamine 2,3-dioxygenase (IDO) with current tumor markers for the primary diagnosis of early-stage endometrial cancer. Methods: A prospective cross-sectional study was conducted between January 2020 and November 2020. A total of 59 patients (38 women newly diagnosed with early-stage endometrial cancer [study group] and 21 women with benign endometrial pathologies [control group]) were enrolled. Blood samples were collected prior to surgery and underwent immunoassay analysis. Results: Carcinoembryonic antigen (CEA), periostin, and IDO levels were significantly higher in the study group than the control group (P = 0.008, P = 0.034, and P = 0.003, respectively). Receiver operating characteristic curve analysis revealed that IDO, periostin, and CEA were good predictors of early-stage endometrial cancer (AUC = 0.733, 95% CI, 0.602-0.840, P < 0.002; AUC = 0.668, 95% CI, 0.533-0.785, P = 0.018; and AUC = 0.709, 95% CI, 0.576-0.820, P = 0.002, respectively). Correlation analysis revealed no significant correlation of any biomarker with age or body mass index in either the control or study group. Conclusion: Serum CEA, periostin, and IDO levels were significantly higher in women with endometrial cancer than in those without cancer. These results may help identify new markers for diagnosing endometrial cancer.eninfo:eu-repo/semantics/closedAccessendometrial cancerindoleamine 2,3-dioxygenaseneopterinperiostintenascin-Ctumor biomarkersYKL-40Article15534174243366084810.1002/ijgo.136662-s2.0-85102931722Q1WOS:000631925300001Q1